ArticleJournal of medicinal chemistry2008

Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.

Sanjeev Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.